NasdaqGS - Nasdaq Real Time Price USD

Jazz Pharmaceuticals plc (JAZZ)

109.36
-0.93
(-0.85%)
As of 12:03:00 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for JAZZ

Recent News: JAZZ

View More
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®

Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®
Insider Monkey yesterday
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
PR Newswire 3 days ago
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
PR Newswire 3 days ago
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?

Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
Zacks 8 days ago
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
PR Newswire 10 days ago
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
PR Newswire 10 days ago
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
PR Newswire 15 days ago
3 of Wall Street’s Favorite Stocks with Mounting Challenges

3 of Wall Street’s Favorite Stocks with Mounting Challenges
StockStory 18 days ago
Insiders Pour Millions into These 3 Stocks — Here’s Why They Draw Plaudits Across the Board

Insiders Pour Millions into These 3 Stocks — Here’s Why They Draw Plaudits Across the Board
TipRanks 21 days ago
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR Newswire 22 days ago
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook

JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook
StockStory 25 days ago
View More

Related Tickers

INCY Incyte Corporation
68.50
-1.04%
 
CYTK Cytokinetics, Incorporated
33.72
+1.55%
 
BMRN BioMarin Pharmaceutical Inc.
57.08
-0.35%
 
ASND Ascendis Pharma A/S
172.81
+1.11%
 
PCVX Vaxcyte, Inc.
34.70
+0.70%
 
ARGX argenx SE
583.15
-0.62%
 
AXSM Axsome Therapeutics, Inc.
105.58
-0.63%
 
IONS Ionis Pharmaceuticals, Inc.
35.51
-0.31%
 
ALNY Alnylam Pharmaceuticals, Inc.
306.45
+0.58%
 
BPMC Blueprint Medicines Corporation
128.06
-0.12%